SCHEMBL6243649

SCHEMBL6243649

[CH2]C(=O)Oc1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
LMNA P02545 2/20 0.42
P4HTM Q9NXG6 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NAPRT Q6XQN6 1/20 0.42
GAA P10253 1/20 0.41
KDM4E B2RXH2 3/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
METAP1 P53582 1/20 0.41
BLM P54132 1/20 0.41
HIF1A Q16665 1/20 0.41
DOHH Q9BU89 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.40
NPC1 O15118 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL450118 0.83 CES2 (0.46) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL11865903 0.83 CES2 (0.46) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL101751 0.81 LMNA (0.48) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL28960343 0.81 CES2 (0.45) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL3676096 0.81 CES2 (0.45) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL2523378 0.79 CES2 (0.43) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL253858 0.79 CES2 (0.43) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL7521569 0.79 CES2 (0.48) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL7351837 0.79 CES2 (0.43) CES2CES1LMNAP4HTML3MBTL1
SCHEMBL519065 0.79 CES2 (0.43) CES2CES1LMNAP4HTML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-56138184-A None JP disclosed
WO-2005040095-A1 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV ASTRAZENECA AB (SE) 2005-05-06 WO disclosed
WO-2002079176-A1 PROCESS FOR 2,4-DISUBSTITUTED-1,3,4-OXADIAZOLINE-5-THIONE AND 5-ONE COMPOUNDS DOW AGROSCIENCES LLC (US) 2002-10-10 WO disclosed
WO-2002072559-A1 PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS ROHM AND HAAS COMPANY (US) 2002-09-19 WO disclosed
US-20010039343-A1 Process to intermediates for biologically active compounds MULVIHILL MARK JOSEPH (US) 2001-11-08 US disclosed
WO-2001056358-A2 ENHANCED PROPERTIED PESTICIDES ROHM AND HAAS COMPANY (US) 2001-08-09 WO disclosed
WO-2001055082-A2 INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS ROHM AND HAAS COMPANY (US) 2001-08-02 WO disclosed
JP-S56138184-A INDOLE DERIVATIVE KOWA CO 1981-10-28 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039343-A1 Process to intermediates for biologically active compounds DDT, CYP4X1, CYP1B1 CES2 49/4885CES1 258/4885LMNA 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.